Deutenzalutamide clinical trials
Deutenzalutamide is named as an intervention in 2 current clinical trials in our China, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia and Israel registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Metastatic Castration-resistant Prostate Cancer.
How Deutenzalutamide works
All drug targets →- COVID-19Phase 3
- Prostate cancerPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594421, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Deutenzalutamide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Deutenzalutamide
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110 · Metastatic Castration-resistant Prostate Cancer
|
Phase 3 | Recruiting | AstraZeneca | UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel |
|
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
NCT07907653 · ClinicalTrials.gov ↗ · Prostate Cancer (Adenocarcinoma)
|
Phase 2 | Not yet open | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Deutenzalutamide
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Deutenzalutamide trials
How many clinical trials are testing Deutenzalutamide?
2 current trials in our China, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia and Israel registers name Deutenzalutamide as a drug or biological intervention, as of the registry sync on 31 October 2026. Completed and withdrawn studies are not counted.
Are Deutenzalutamide trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China, 1 with sites in UK, 1 with sites in USA, 1 with sites in India, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Deutenzalutamide clinical trials?
AstraZeneca (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Deutenzalutamide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Deutenzalutamide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Deutenzalutamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 31 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.